- 1 Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal
- 2 insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and
- 3 meta-analysis of randomized clinical trials
- 4
- 5 Mansur A. Ramalan^{1*}
- 6 Musa Baba Maiyaki^{1,2,3}
- 7 Ibrahim D Gezawa^{1,2},
- 8 Andrew E Uloko^{1,2},
- 9 ¹ Department of Internal Medicine, Aminu Kano Teaching Hospital, Kano, Kano State,
- 10 Nigeria
- 11 ² Department of Internal Medicine, Bayero University, Kano, Kano State, Nigeria
- 12 ³ Africa Center of Excellence for Population Health and Policy Bayero University Kano, Kano
- 13 State, Nigeria
- 14 * Corresponding author
- 15 E-mail: <u>mmramalan@gmail.com</u> (MAR)
- 16
- 17 Author contribution
- 18
- 19 Mansur Aliyu Ramalan, Conceptualization, Methodology, Project administration, Writing –
- 20 original draft, Writing review & editing, **Ibrahim D Gezawa**, Writing original draft, Writing
- 21 review & editing, Andrew Uloko Writing original draft, Writing review & editing, Musa
- 22 Babamaiyaki, Methodology, Writing review & editing
- 23 Prospero registration number CRD42022363619

24			
25			
26			
27			
28			

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 Background

Blood glucose control is a major goal of management demonstrated by many guidelines and 32 results of clinical trials. Achieving good glycaemia is associated with reduction of the risks of 33 34 cardiovascular disease. Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are now 35 important parts of many guidelines for the management of diabetes mellitus because of their cardiovascular benefit. Basal insulin in have now been combined with GLP-1 RAs in fixed 36 37 ration combinations in single pens. We aim to conduct a meta-analysis and systematic review of randomized control clinical trials the evaluate the therapeutic efficacy of glucagon-like 38 peptide-1 receptor agonists combined with basal insulin therapy in treating type 2 diabetes, 39 using a fixed-ratio combination of the two. 40

41 Method and data analysis

It is anticipated that a systematic search of the literature will be conducted on the following 42 electronic databases will be searched: The Cochrane Library, PubMed, Google Scholar, and 43 44 EMBASE. We plan to include only randomized control clinical trials on GLP 1RA, fixed ratio combination of basal insulin and GLP 1RA and basal insulins alone. A validated study 45 design-specific critical appraisal tool will be used to assess the risk of bias in individual 46 studies. The systematic review will be performed in accordance with the JBI guideline for 47 48 prevalence and incidence review. The review will be reporting following the Preferred 49 Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline.

50

51

52 Introduction

In patients with T2DM, blood glucose control is a major goal of management demonstrated by many guidelines and results of clinical trials.(1–3) It has been reported in the literature that micro and macro vascular risks increased with poor glycaemic control. The UKPDS for instance found that improved control of blood glucose or blood pressure reduced the risk of major diabetic eye disease by one quarter, serious deterioration of vision by nearly one half, early kidney damage by one third, strokes by one third, and death from diabetes-related causes by one third.(3)

Over the past few decades, the cardiovascular benefits and lower risks of hypoglycaemia of the Glucagon like peptide 1 receptor agonists (GLP-1 RAs) has made them a major part of many guidelines for the management of diabetes mellitus.(4,5) Basal insulins on the hand have been shown to be highly effective in glycaemic control of patients with T2DM.(6) They reduce fasting blood glucose levels and improve glycaemia but are associated with higher risks of hypoglycaemia compared to the GLP-1 RAs.

Recently the potential benefit of using the combination of GLP-1 RAs and basal insulin in the
pharmacological treatment of type 2 diabetes mellitus has been shown to improve glycemic
control. (7,8)

69 There are several combinations of GLP-1 RAs and basal insulins in fixed ratio combinations70 available for use in a single injection pen currently available. (9)

The potential benefits of combining GLP-1RAs with basal insulin in fixed ratio combinations
is to Improve glycaemia, while reducing the risks of hypoglycaemia and lower the risks of
weight gain.(9)

- 74 This protocol intends to review the therapeutic efficacy, safety and cardiovascular benefit of
- 75 the fixed ratio combinations of the GLP-1 RAs and basal insulins in comparison with the GLP-
- 76 1 RAs alone or basal insulins alone.

77 Aim and objectives

This study aims to conduct a systematic review and meta-analysis of randomized controlled clinical trials with the aim of evaluating the therapeutic efficacy of glucagon-like peptide-1 receptor agonists combined with basal insulin therapy in treating type 2 diabetes, using a fixedratio combination of the two.

82 The secondary objectives of the systematic review will include:

1. to determine the cardiovascular outcome of a fixed-ratio combination of glucagon-like
peptide-1 receptor agonist versus basal insulin alone or in combination with prandial insulin
therapy for the treatment of type 2 diabetes

2. to determine the incidence of adverse events in patients with type 2 diabetes on a fixed-ratio
combination of glucagon-like peptide-1 receptor agonist versus basal insulin alone or in
combination with prandial insulin

3. to compare the effects of a fixed-ratio combination of glucagon-like peptide-1 receptor
agonist versus basal insulin alone or in combination with prandial insulin on weight and
hypoglycemia in patients with type 2 diabetes.

92 Method

93 Registration and reporting of the review findings

94	The protocol for this review has been registered with Prospero with the registration number
95	CRD42022363619. We will use PRISMA (Preferred Reporting Items for Systematic Reviews
96	and Meta-Analyses)(10) to report the findings of this study. In order to conduct this systematic
97	review, we will follow the guidelines set by the Joanna Briggs Institute (JBI) for systematic
98	reviews.(11)

99 Study eligibility

- Population, intervention, comparison, and outcome (PICO) protocols will be used to evaluatestudy eligibility.
- 102 Population Randomized controlled trials conducted on adult T2DM patients.
- 103 Intervention GLP-1RA and basal insulin, or GLP-1RA alone or basal insulin alone.
- 104 Comparison T2DM patients using GLP-1RA and basal insulin will be compared to GLP-1RA
- alone or basal insulin alone (comparator).
- 106 Outcome Reduction in HbA1c from baseline, reduction in fasting plasma glucose levels,
 107 hypoglycemia, and weight gain.

108 Search strategy

109 The Preferred Reporting Items for Systematic Reviews and Metanalyses checklist will be 110 utilized for the systematic review of the literature. Searches of the literature will be conducted 111 in the Cochrane Library, PubMed, Google Scholar, and EMBASE. The research will be 112 randomized control trials only. There will be no language restrictions on the studies and articles 113 selected for the review. The search strategy will include terms for GLP 1 agonists and basal 114 insulin fixed-dose combination, GLP 1 agonists, basal insulin, basal-bolus insulin, prandial

- insulin, cardiovascular benefits, adverse events, hypoglycemia, weight reduction, efficacy, and
- adherence.

117 Population characteristics

- 118 (1) Patients with type 2 diabetes who were initiated on the fixed ratio combination or switched
- to the fixed ratio combination for at least 12 weeks
- 120 (2) Patients with type 2 diabetes either initiated on basal insulin or prandial insulin with or
- 121 without basal insulin or switched to basal insulin or prandial insulin with or without basal
- insulin for at least 12 weeks
- 123 (3) Outcome measures: therapeutic efficacy, cardiovascular outcome, adverse events and124 effects on weight.
- Basal insulin or prandial insulin with or without basal insulin or switched to basal insulin orprandial insulin with or without basal insulin for at least 12 weeks
- 127 (4) Secondary outcome measures: Therapeutic efficacy, cardiovascular outcome, adverse128 events and effects on weight

129 Research question

- 130 What is the therapeutic efficacy of GLP1 agonist and basal insulin fixed-dose combinations in
- the treatment of type 2 diabetes compared to GLP1 agonists or basal insulin alone?

What is the cardiovascular benefit of using GLP1 agonist and basal insulin fixed-dosecombinations in the treatment of type 2 diabetes compared to GLP1 agonists or basal insulinalone?

What is the burden of adverse effects of GLP1 agonist and basal insulin fixed-dose combinations in the treatment of type 2 diabetes compared to GLP1 agonists or basal insulin alone?

138 Eligibility criteria

139 Inclusion criteria:

- 140 Randomized controlled clinical trials that provide estimates of efficacy, adverse events or141 cardiovascular outcomes and effects on weight.
- 142 Outcome index: therapeutic efficacy, cardiovascular outcome, adverse events and effects on143 weight.

144 Exclusion criteria:

Qualitative studies, case reports, case series, case-control studies, conference proceedings, prospective and retrospective observational studies, descriptive and analytical cross-sectional studies. Expert opinions, and randomized control trials not reporting estimates of therapeutic efficacy, unpublished data, repeated publication of literature, or where the full text is not available. Or where the data cannot be extracted.

150 Language

151 Only studies written in English or with an available English version, or with the possibility of152 translating the full article via Google Translate, will be included.

153 Study period

- 154 We will focus on the past three decades; therefore, we will include studies conducted from
- 155 1st January 1990 to 30th of June 2023.

156 Electronic searches

157 It is anticipated that the following electronic databases will be searched: The Cochrane Library, PubMed, Google Scholar, and EMBASE. The research will be randomized control trials only. 158 There will be no language restrictions on studies and articles selected for the review. The search 159 160 strategy will include terms for GLP 1 agonists and basal insulin fixed-dose combination, GLP 1 agonists, basal insulin, basal-bolus insulin, prandial insulin, cardiovascular benefits, adverse 161 events, hypoglycemia, weight reduction, efficacy, and adherence. (See S1 Appendix). Terms 162 representing similar concepts will be separated using the Boolean operator "OR" while terms 163 representing different concepts will be separated using the Boolean operator "AND". Where 164 the full text of relevant studies cannot be retrieved, efforts will be made to request the full text 165 from study corresponding authors. 166

The literature will be independently screened by 2 researchers to identify articles that meet the 167 inclusion criteria. Firstly, according to the weight of the topic, review the topic summary to 168 exclude irrelevant literature. Then read the full text to select literature according to the inclusion 169 170 and exclusion criteria. Finally, two people will check the results, and if their opinions don't agree, a third party will take the decision. The following contents will be extracted from the 171 included literature: first author, year of publication, age of study subjects, study site, estimates 172 of efficacy, adverse events, effects of weight and hypoglycaemia. The reasons for the exclusion 173 174 of full-text articles will be given. PRISMA flow diagrams will be used to describe and 175 summarize the search results and selection process. A table will be used to report the details of all the included studies. 176

177 Other searches

A hand search will be conducted for unpublished studies/grey literature using the keywords
found in the study through Google Scholar and gray literature databases such as WHO Library,
OpenSIGLE, and Open Gray.

181 Risk of bias

The risk of bias in the included studies will be assessed using the Joanna Briggs Institute (JBI)
tool. We will describe any assessment of the risk of bias that may affect the cumulative
evidence (e.g., publication bias, selective reporting within studies).

185 Data extraction

The primary changes in HbA1c from baseline to the end of treatment. Changes in the levels of fasting plasma glucose from baseline to the end of the study, changes in the body weights of the participants and the proportion of participants reaching the HbA1c target <7.0% at the end of the study. Reported and documented hypoglycaemic episodes during the period of treatment.

190 Strategy for data synthesis

A quantitative meta-analysis will be performed on the estimates of efficacy, adverse events, effects of weight and hypoglycaemia in patients with type 2 diabetes using Stata17.0. Pooled estimates of weighted means differences (WMDS) and 95% CI for continuous outcomes; changes in HbA1c, FPG, as well as the pooled risk ratios (RR) of dichotomous outcomes including the proportion of participants achieving HbA1c target values and the risks of hypoglycaemia will be calculated.

Heterogeneity will be assessed using the I^2 statistic for each analysis, with the significance level set at P<0.05. If there is found to be significant heterogeneity between the studies, the random effects model will be used, or these studies will be divided into specific subgroups,

based on different factors. The potential risks of publication bias will be evaluated byconstructing funnel plots of primary outcomes with asymmetry assessed by Egger's test.

A forest plot will be used to illustrate the distribution of the outcome and effect sizes obtained
 from each published study. In addition, publication bias will also be assessed, and a sensitivity
 analysis carried out.

205 Analysis of subgroups or subsets

A sensitivity analysis comparing the intervention arm GLP-1 agonist and basal insulin with basal insulin therapy or basal-bolus insulin is planned. Subgroup analysis will also be conducted. The efficacy of individual FRC drugs will be reported using a forest plot.

209 Assessment of certainty of evidence

To assess the quality of the synthesised findings, we will use the GRADE instrument and Gradepro Software. Studies included in the analysis will be assessed for their design, heterogeneity, consistency, directness, precision, and publication bias. A quality rating will be assigned to the evidence: high, moderate, low or very low.

214 Discussion

The proposed study will provide the first insight into the comparative efficacy, safety, and adverse effects profile of the fixed ration combination of GLP-1RA and basal insulin in comparison to basal insulin alone or GLP1-RA alone. Also, the specific cardiovascular benefit of the fixed ration combination of the GLP-1 receptor agonist with basal insulin has not been completely elucidated although the cardiovascular benefit of GLP-1 RA has been well established.(9) The fixed-ratio combination of GLP1 RA and basal insulin is relatively new but in previous studies that compared with the basal-bolus insulin regimen, the combination of

- GLP-1RA and basal insulin displayed a similar benefit in lowering HbA1c with a 33% lower
- risk of hypoglycemia and 5.66 kg less body weight gain.(12)
- 224 The combination of basal insulin GLP -1 RA is a synergistic effect that is produced by the
- activity of the basal insulin principally suppressing fasting plasma glucose, and the GLP 1 RA
- that acts by suppressing the postprandial glucose excursions.

227

- 228 We expect that the study will be conducted using a systematic approach utilizing a well-defined
- 229 protocol and following a standard algorithm for data collection and analysis. Among the
- potential limitations, heterogeneity in individual studies may be encountered due to the quality
- of the study designs, definitions used, or evaluation methods. A detailed narrative report will,
- 232 however, be provided highlighting these discrepancies and providing suggestions for
- 233 improving future research.

234 Acknowledgments

235 Nil

236 References

- Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6year study. Diabetes Res Clin Pract. 1995 May;28(2):103–17.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of
 Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine. 2008
 Oct 9;359(15):1577–89.
- Leslie RDG. United Kingdom Prospective Diabetes Study (UKPDS): what now or so
 what? Diabetes Metab Res Rev. 1999 Jan;15(1):65–71.
- Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 Receptor Agonists for the
 Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
 Circulation. 2022 Dec 13;146(24):1882–94.
- 2495.Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent250cardiovascular outcomes trials. Postgrad Med J. 2020 Mar 1;96(1133):156–61.
- 251 6. Hedrington MS, Pulliam L, Davis SN. Basal Insulin Treatment in Type 2 Diabetes.
- 252 Diabetes Technol Ther. 2011 Jun;13(S1):S-33-S-42.

- 7. Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1
 receptor agonist: is this the end of basal insulin alone in the treatment of type 2
 diabetes? Diabetol Metab Syndr. 2018 Dec 3;10(1):26.
- Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in
 Diabetes—2021. Diabetes Care. 2021 Jan 1;44(Supplement 1):S111–24.
- 2589.Lisco G, de Tullio A, Guastamacchia E, Triggiani V. Fixed-Ratio Combinations of Basal259Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from
- the Literature. Endocr Metab Immune Disord Drug Targets. 2021 Apr;21(4):626–46.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst
 Rev. 2021 Dec 29;10(1):89.
- Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Systematic reviews of prevalence and
 incidence. Joanna Briggs Institute reviewer's manual Adelaide, South Australia: The
 Joanna Briggs Institute. 2017:5–1.
- 267 12. Jung HN, Cho YK, Min SH, Kim HS, Kim YJ, Park JY, et al. Free Versus Fixed-Ratio
 268 Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes
 269 Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect
- 270 Treatment Comparison. Front Endocrinol (Lausanne). 2022 May 20;13.
- 271
- 272 Source of funding Self funded
- 273 Supporting information
- 274 Appendix 1
- 275 PRISMA Check list
- 276